Deborah Mukherji· @dmukherji · X·· 2 天前评分90
正文 · 原文
Promising updated data in NEPC at #ESMO26
In KEYNOTE-365, pembrolizumab + carboplatin/etoposide showed higher ORR, longer rPFS and OS (10.2 vs 7.1 mo) vs chemotherapy alone #GunhildVonAmsberg @OncoAlert
279 浏览 · 10 赞 · 6 转发 · 0 回复
会议摘要
Updated results from the phase 1b/2 KEYNOTE-365 cohort I: Pembrolizumab (pembro) + carboplatin and etoposide chemotherapy (chemo) or chemo alone for neuroendocrine prostate cancer (NEPC)
https://esmocongress.esmo.org来源：Deborah Mukherji · x.com